TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05112848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70).
Study: NCT05998655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele nursing
Description: In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets.
Study: NCT04826458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TreC-Onco
Description: At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission.

Intervention type: OTHER
Group type: OTHER
Intervention: Paper diary
Description: Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
Study: NCT06364761

Intervention type: PROCEDURE
Intervention: Bag in the lens cataract surgery
Description: Cataract surgery using the Morcher 89A intraocular lens
Study: NCT05796882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Diet Ad Libitum
Description: Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Standard Care
Description: Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
Study: NCT06191965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
Study: NCT05028049

Intervention type: OTHER
Intervention: plateau areas
Description: Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)

Intervention type: OTHER
Intervention: plateau areas
Description: Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
Study: NCT05656586

Intervention type: OTHER
Intervention: observational-- no intervention
Description: observational
Study: NCT00893854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclophenac
Study: NCT06231394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal pelvic floor rehabilitation
Description: A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal pelvic floor rehabilitation
Description: A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multimodal pelvic floor rehabilitation
Description: A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
Study: NCT05149443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based mHealth-intervention (app)
Description: Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based mHealth-intervention (app)
Description: After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days.
Study: NCT05486455

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT scan
Description: baseline, 1-year, 3-year and 5-year low-dose CT scan
Study: NCT04516512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: For each participants to the research a peripherical blood draw will be performed
Study: NCT05225974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide injection(Victoza®)
Description: At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
Study: NCT05410366

Intervention type: OTHER
Intervention: Safe harbor clinical practice guideline
Description: A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
Study: NCT05304611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.
Study: NCT00893854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Study: NCT05582681

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cepheid POC HCV Viremia (RNA) test
Description: The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HCV education from a health care provider
Description: HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV education from a health care provider
Description: HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir and Pibrentasvir
Description: G/P will be provided for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir
Description: G/P will be provided for 8 weeks.
Study: NCT05812352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio kit
Description: MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional flashcard
Description: Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
Study: NCT05304611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Description: Administered one time via subcutaneous route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L9LS (VRC-MALMAB0114-00-AB) intravenous injection
Description: Administered one time via intravenous route.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered one time via subcutaneous route.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered one time via subcutaneous route.
Study: NCT05812352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person training
Description: Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
Study: NCT06475768

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Echocardiogram
Description: Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Echocardiogram
Description: Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
Study: NCT05379894

Intervention type: PROCEDURE
Intervention: Percutaneous nephrolithotripsy
Description: Extraction of kidney stones through skin using nephroscope

Intervention type: PROCEDURE
Intervention: Percutaneous nephrolithotripsy
Description: Extraction of kidney stones through skin using nephroscope
Study: NCT06475768

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Echocardiogram
Description: Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Imaging (cMRI)
Description: Non-invasive imaging scan used to examine function and structure of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Imaging (cMRI)
Description: Non-invasive imaging scan used to examine function and structure of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Imaging (cMRI)
Description: Non-invasive imaging scan used to examine function and structure of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Elastography (cMRE)
Description: Non-invasive imaging scan used to measure myocardial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Elastography (cMRE)
Description: Non-invasive imaging scan used to measure myocardial stiffness

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Elastography (cMRE)
Description: Non-invasive imaging scan used to measure myocardial stiffness
Study: NCT05771129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.
Description: Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
Study: NCT06563310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) with Veritable-NF
Description: Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI with Sham-NF
Description: Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
Study: NCT05640856

Intervention type: PROCEDURE
Intervention: intubation
Description: Endotracheal tube placement

Intervention type: PROCEDURE
Intervention: intubation
Description: Endotracheal tube placement
Study: NCT05677295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Duloxetine 30 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Imipramine 25 mg per day
Study: NCT05067452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food support
Description: Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-management
Description: Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition
Study: NCT05711927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNOO Smart Sleeper
Description: Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Traditional bassinet
Description: Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.